Tournament Update of the SPAC Sixteen Matches
We have a pretty decent match going on between BofA and Chardan. Chardan took the lead this morning, but BofA came back and is now leading 57% to 43%. Is Chardan the Cinderella Story of this Tournament? There’s still time to cast your vote….
In other surprising news, B. Riley is handily beating J.P. Morgan right now with 60% of the votes to JPM’s 40%. (Although maybe not so surprising since B. Riley has been on more recent SPAC transactions than JPM)
Credit Suisse and EarlyBirdCapital have commanding leads with both rounding up 100% of the votes cast in their favor, while Deutsche Bank, Cantor and Goldman Sachs all look likely to win their matches.
Voting ends at Midnight so there’s still time…
Round One Matches Rules/Rankings/Details
AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...
At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...
Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...
At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...
Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...